Unknown

Dataset Information

0

Engineered macrophages as near-infrared light activated drug vectors for chemo-photodynamic therapy of primary and bone metastatic breast cancer.


ABSTRACT: Patients with primary and bone metastatic breast cancer have significantly reduced survival and life quality. Due to the poor drug delivery efficiency of anti-metastasis therapy and the limited response rate of immunotherapy for breast cancer, effective treatment remains a formidable challenge. In this work, engineered macrophages (Oxa(IV)@ZnPc@M) carrying nanomedicine containing oxaliplatin prodrug and photosensitizer are designed as near-infrared (NIR) light-activated drug vectors, aiming to achieve enhanced chemo/photo/immunotherapy of primary and bone metastatic tumors. Oxa(IV)@ZnPc@M exhibits an anti-tumor M1 phenotype polarization and can efficiently home to primary and bone metastatic tumors. Additionally, therapeutics inside Oxa(IV)@ZnPc@M undergo NIR triggered release, which can kill primary tumors via combined chemo-photodynamic therapy and induce immunogenic cell death simultaneously. Oxa(IV)@ZnPc@M combined with anti-PD-L1 can eliminate primary and bone metastatic tumors, activate tumor-specific antitumor immune response, and improve overall survival with limited systemic toxicity. Therefore, this all-in-one macrophage provides a treatment platform for effective therapy of primary and bone metastatic tumors.

SUBMITTER: Huang Y 

PROVIDER: S-EPMC8280231 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4775857 | biostudies-other
| S-EPMC6831479 | biostudies-literature
| S-EPMC5483882 | biostudies-literature
| S-EPMC5347683 | biostudies-literature
| S-EPMC6964518 | biostudies-literature
| S-EPMC7441577 | biostudies-literature
| S-EPMC7179334 | biostudies-literature
| S-EPMC3749836 | biostudies-literature
| S-EPMC7693251 | biostudies-literature
| S-EPMC9064574 | biostudies-literature